1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Biogen Acquires Alcyone Therapeutics

M&A Deal Summary

Biogen Acquires Alcyone Therapeutics

On November 14, 2025, Biogen acquired life science company Alcyone Therapeutics

Acquisition Highlights
  • This is Biogen’s 10th transaction in the Life Science sector.
  • This is Biogen’s 7th transaction in the United States.
  • This is Biogen’s 3rd transaction in Massachusetts.

M&A Deal Summary
Date 2025-11-14
Target Alcyone Therapeutics
Sector Life Science
Buyer(s) Biogen
Deal Type Add-on Acquisition

Target

Alcyone Therapeutics

Lowell, Massachusetts, United States
Alcyone Therapeutics develops precision gene-based therapies for complex neurological conditions, with an emphasis on intrathecal delivery and cerebrospinal fluid-based dosing technologies. Alcyone Therapeutics was founded in 2012 and is headquartered in Lowell, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Biogen

Cambridge, Massachusetts, United States
Category Company
Founded 1978
Sector Life Science
Employees7,605
Revenue 9.7B USD (2024)
DESCRIPTION
Entrance to Biogen office in Weston, Massachusetts.
Entrance to Biogen office in Weston, Massachusetts.

Biogen is a biopharmaceutical company focused on discovering, developing, and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen was founded in 1978 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 10 of 10
Sector: Life Science M&A 10 of 10
Type: Add-on Acquisition M&A Deals 8 of 8
State: Massachusetts M&A 3 of 3
Country: United States M&A 7 of 7
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-05-22 HI-Bio

South San Francisco, California, United States

HI-Bio is a clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). The company’s felzartamab is a CD38-targeted antibody shown in clinical studies to deplete CD38+ cells, including plasma and natural killer (NK) cells, which are implicated in a range of indications including antibody-mediated rejection (AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary membranous nephropathy (PMN). HI-Bio is based in South San Francisco, California.

Buy -
Mergr

Solution for

Product

Company

Legal